Compare Abbott Laboratories (ABT) vs Visa Inc (V) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Visa Inc — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Visa Inc trades at $347.46 (market cap $669.79B). The key difference: Visa Inc is far larger — about 4× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | V | |
|---|---|---|
Market Cap | $166.94B | $669.79B |
Sector | Health | Financials |
52-Week High | $136.62 | $362.13 |
52-Week Low | $82.57 | $295.52 |
Enterprise Value | $193.69B | $680.39B |
Dividend Yield | 2.63% | 0.76% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Visa (V) trades at $348.16, down 2.54% over the past day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.31 surpassing the $3.10 expectation. Revenue grew to $40 billion in 2025, supporting a net income margin of 51.68%. Analyst sentiment remains overwhelmingly positive, with 85% recommending Buy and a consensus price target of $392.50, suggesting 13% upside. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships.
Visa presents a favorable long-term investment opportunity due to its robust profitability, expanding revenue, and strategic initiatives in digital payments. Risks include competitive pressures from fintech and regulatory scrutiny, but strong institutional support and consistent earnings growth underpin a positive outlook. The current valuation, while premium, is justified by high margins and market leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
